Why the study?
To assess different bridging anticoagulation therapies early after mechanical heart valve replacement in Chinese patients.
Does low-molecular-weight heparin bridging anticoagulation affect the incidence of bleeding and thromboembolic events compared to unfractionated heparin in patients after mechanical heart valve replacement?
Does low-molecular-weight heparin bridging anticoagulation affect the incidence of bleeding and thromboembolic events compared to unfractionated heparin in patients after mechanical heart valve replacement?
In Chinese patients undergoing mechanical heart valve replacement, LMWH bridging anticoagulation increases bleeding risk compared to UFH, though it may offer trends toward faster achievement of target INR and shorter hospital stays.
No takes yet. Share an insight, caveat, or question.
LMWH bridging may raise bleeding risk after MHVR; leaves open optimal regimen selection pending randomized data.
Li et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: